Dr. Ann Ginsberg

Dr. Ann Ginsberg joined the foundation in 2020 and leads the Tuberculosis team’s vaccine strategy and oversees its vaccine investment portfolio, working with Dr. Nina Russell, director of the foundation’s Tuberculosis and HIV programs. Ann also oversees the Collaboration for TB Vaccine Discovery, the foundation’s major mechanism for accelerating TB vaccine discovery and development through collaborations with the research and development community.

Before joining the foundation, Ann served as chief medical officer at Aeras, a nonprofit biotech organization focused on developing novel TB vaccines for at-risk populations globally, where she oversaw, in collaboration with key partners, two recent landmark clinical efficacy trials. Earlier, she served as chief medical officer at another nonprofit biotech organization, the Global Alliance for TB Drug Development, where she led the early clinical development of the now-licensed TB drug pretomanid. She began her career in TB at the National Institute of Allergy and Infectious Diseases within the National Institutes of Health, as a program officer and then as chief of the Respiratory Diseases Branch. She got her start in product development at Merck as director of project management.

Ann earned an A.B. cum laude from Harvard University, a Ph.D. in molecular biology from Washington University School of Medicine in St. Louis, and an M.D. from Columbia University’s College of Physicians and Surgeons.